In-Licensing Opportunity Assessment in a Subsegment of Anticoagulant Agents for the EU-5 Market

Publications
Category:
Published on:
May 2, 2020
Written by:
Joris Pezzini

When our client, a renowned European pharma company, was interested in an in-licensing opportunity to drive its future growth while achieving significant commercial synergies, Alira Health performed a thorough analysis to understand the sales potential and value.

Read on to see how Alira Health’s in-depth analysis helped our client move forward with confidence.

For more information or for a PDF of this infographic, contact Joris Pezzini.

To know more about Alira Health Management Consulting services

Click here

Related news

News February 7, 2024
Alira Health Advises Aesculapius Farmaceutici Srl in Its Acquisition by Ceres Pharma NV
We are pleased to have represented as transaction advisor Aesculapius, a leading Italian pharmaceutical company active in the development and distribution of prescription drugs, OTC(...)
Pharma Transaction Advisory
News January 26, 2024
Alira Health’s CDD Supports Alcami Acquisition of Pacific Pharmaceutical Services
We are pleased to have been an advisor on Alcami’s acquisition of Pacific Pharmaceutical Services (PPS). Alira Health advised Alcami, a leading Contract Development Manufacturing(...)
CDD CDMO Pharma
Events January 22, 2024
Pharmapack Europe
Connect with our Drug Delivery Systems and CDMO experts Aude Ouensanga, Giulia Valsecchi, and Michal Raciborski on site at Pharmapack Europe.
CDMO Drug Delivery Pharma
Case Studies January 18, 2024
Pharma Company Succeeds in Adding Medicine to World Health Organization Essential Medicines List
A pharma company with a blood disorder treatment needed support to submit a value dossier to the WHO to add a medicine to the Essential Medicines List.
Market Access Pharma
Case Studies January 8, 2024
Pharma Company Extends to New Markets through Strategic Licensing Agreements
A Swedish pharma company saw a market opportunity to expand access to its proprietary product outside of the Nordics and sought support developing strategic licensing deals.
Market Access Pharma
Blog November 17, 2023
Misconceptions About Patient-Centric Co-Design
Many people have misconceptions about patient-centric co-design, and these misconceptions are holding companies back.
Co-Design Digital Health MedTech Patient Centricity Pharma
Blog November 2, 2023
The Impact of New Treatment Approvals in Oncology on Relative Survival Rates for EU Patients
This article explores the relationship between the number of new cancer treatment approvals and the five-year relative survival of cancer patients across the European Union (EU).
Oncology Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.